# Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Balding Scalp Including 12-month Follow-up

> **NCT02547363** · PHASE3 · COMPLETED · sponsor: **LEO Pharma** · enrollment: 373 (actual)

## Conditions studied

- Actinic Keratosis

## Interventions

- **DRUG:** LEO 43204 gel
- **DRUG:** Vehicle gel

## Key facts

- **NCT ID:** NCT02547363
- **Lead sponsor:** LEO Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-11
- **Primary completion:** 2016-08-17
- **Final completion:** 2017-08
- **Target enrollment:** 373 (ACTUAL)
- **Last updated:** 2025-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02547363

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02547363, "Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Balding Scalp Including 12-month Follow-up". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02547363. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*